CN113039200B - 改进的fviii融合蛋白及其应用 - Google Patents

改进的fviii融合蛋白及其应用 Download PDF

Info

Publication number
CN113039200B
CN113039200B CN201980033170.0A CN201980033170A CN113039200B CN 113039200 B CN113039200 B CN 113039200B CN 201980033170 A CN201980033170 A CN 201980033170A CN 113039200 B CN113039200 B CN 113039200B
Authority
CN
China
Prior art keywords
fusion protein
seq
protein according
amino acid
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980033170.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113039200A (zh
Inventor
苏鸿声
王晓山
刘宾
陈宪
李相�
朱鹿燕
王淑亚
王双
王文文
黄灵丽
王齐磊
胡海涛
张莉莉
高洁
任子甲
肖春峰
王亚里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Shengsi Biotechnology Co ltd
Original Assignee
Zhengzhou Shengsi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Shengsi Biotechnology Co ltd filed Critical Zhengzhou Shengsi Biotechnology Co ltd
Priority to CN202310860049.3A priority Critical patent/CN117467019A/zh
Publication of CN113039200A publication Critical patent/CN113039200A/zh
Application granted granted Critical
Publication of CN113039200B publication Critical patent/CN113039200B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980033170.0A 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用 Active CN113039200B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310860049.3A CN117467019A (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18
CN201810481941X 2018-05-18
PCT/CN2019/087156 WO2019219049A1 (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310860049.3A Division CN117467019A (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Publications (2)

Publication Number Publication Date
CN113039200A CN113039200A (zh) 2021-06-25
CN113039200B true CN113039200B (zh) 2023-07-25

Family

ID=68539524

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980033170.0A Active CN113039200B (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用
CN202310860049.3A Pending CN117467019A (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310860049.3A Pending CN117467019A (zh) 2018-05-18 2019-05-16 改进的fviii融合蛋白及其应用

Country Status (9)

Country Link
US (1) US12440572B2 (enExample)
EP (1) EP3816181A4 (enExample)
JP (2) JP2021530437A (enExample)
KR (1) KR102575788B1 (enExample)
CN (2) CN113039200B (enExample)
BR (1) BR112020023168A2 (enExample)
MA (1) MA53020A (enExample)
MX (1) MX2020012103A (enExample)
WO (1) WO2019219049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534563A1 (en) 2022-05-25 2025-04-09 Jiangsu Gensciences Inc. Fviii fusion protein conjugate having extended half-life and use thereof
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008480A2 (en) * 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN105153313A (zh) * 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
CN106279437A (zh) * 2016-08-19 2017-01-04 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
CN103172745A (zh) 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
CN104519912A (zh) 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CN103539860B (zh) 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
SG11201805497QA (en) * 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153313A (zh) * 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
WO2014008480A2 (en) * 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN106279437A (zh) * 2016-08-19 2017-01-04 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
MX2020012103A (es) 2021-01-29
KR20210005248A (ko) 2021-01-13
BR112020023168A2 (pt) 2021-02-09
JP2023093634A (ja) 2023-07-04
EP3816181A4 (en) 2022-04-20
CN117467019A (zh) 2024-01-30
MA53020A (fr) 2021-05-05
KR102575788B1 (ko) 2023-09-08
EP3816181A1 (en) 2021-05-05
JP7492780B2 (ja) 2024-05-30
CN113039200A (zh) 2021-06-25
US12440572B2 (en) 2025-10-14
US20210361775A1 (en) 2021-11-25
WO2019219049A1 (zh) 2019-11-21
JP2021530437A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
CN103739712B (zh) 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
JP7492780B2 (ja) 改良されたｆｖｉｉｉ融合タンパク質及びその応用
JP3827713B2 (ja) 凝固因子ｖｉｉｉからなる医薬製剤
ES2657291T3 (es) Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
DK1824988T3 (en) LOCATION-SPECIFIC MODIFICATION OF FVIII
AU2012318292B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
CN110950964B (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
CN113166271A (zh) 具有延长半衰期的融合多肽缀合物
HK1213273A1 (zh) 重組因子viii製劑
KR20140083036A (ko) 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
RU2789085C2 (ru) Улучшенный белок слияния fviii и его применение
CN120051296A (zh) 用于施用到软组织的因子ix变体多肽
HK40046100A (en) Improved fviii fusion protein and use thereof
TWI878902B (zh) 具有延長的半衰期的fviii融合蛋白綴合物及其應用
JP2018529760A5 (enExample)
TW202540157A (zh) 具有延長的半衰期的ｆｖｉｉｉ融合蛋白綴合物及其應用
JP2018529760A (ja) 長半減期凝固複合体と関連する方法及び組成物
HK40079628A (en) Subcutaneous administration of factor viii
CN114929261A (zh) 凝血因子viii的皮下施用
HK1154047A (en) Fviii muteins for treatment of von willebrand disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Improved FVIII fusion protein and its application

Granted publication date: 20230725

Pledgee: Shanghai Lianxin Technology Equity Investment Center (Limited Partnership)

Pledgor: Beijing Jike Shengsi Pharmaceutical Technology Co., Ltd.|Zhengzhou Shengsi Biotechnology Co., Ltd.

Registration number: Y2025980026291

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20230725

Pledgee: Shanghai Lianxin Technology Equity Investment Center (Limited Partnership)

Pledgor: Beijing Jike Shengsi Pharmaceutical Technology Co.,Ltd.|Zhengzhou Shengsi Biotechnology Co.,Ltd.

Registration number: Y2025980026291

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Improved FVIII fusion protein and its application

Granted publication date: 20230725

Pledgee: Hangzhou Beicheng Venture Capital Partnership (Limited Partnership)

Pledgor: Beijing Jike Shengsi Pharmaceutical Technology Co.,Ltd.|Zhengzhou Shengsi Biotechnology Co.,Ltd.|Jiangsu Shengsi biopharmaceutical Co.,Ltd.

Registration number: Y2025980040298

PE01 Entry into force of the registration of the contract for pledge of patent right